DSWL [DESWELL INDUSTRIES] SD:
[]
RCON [Recon Technology] 6-K: SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVAL
[SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVAL CONFIDENTIAL May 7, 2020 VIA ELECTRONIC DELIVERY Mr. Shenping Yin Co-founder & CEO Recon Technology, Ltd. King Long International Mansion Building C Room 1902 9 Fulin Road Chaoyang District Beijing 100107, China Dear Mr. Yin: Agreement Maxim ]
CCCL [China Ceramics] 6-K: (Original Filing)
[china ceramics co., ltd. Holder Initial Exercise Date Termination Date Company Section 1 Definitions Purchase Agreement Section 2 Exercise Notice of Exercise a) 1 Exercise Price Exercise Price b) Cashless Exercise c) 2 Bid Price “ VWAP “ 3 d) Mechanics of Exercise DWAC Standard Settlement Period i. ]
CCCL [China Ceramics] 6-K: china ceramics co., ltd. Holder Initial Exercise Date
[china ceramics co., ltd. Holder Initial Exercise Date Termination Date Company Section 1 Definitions Purchase Agreement Section 2 Exercise Notice of Exercise a) 1 Exercise Price Exercise Price b) Cashless Exercise c) 2 Bid Price “ VWAP “ 3 d) Mechanics of Exercise DWAC Standard Settlement Period i. ]
CCCL [China Ceramics] 424B5: (Original Filing)
[Registration No. 333-228182 Prospectus Supplement (To prospectus dated November 14, 2018) China Ceramics Co., Ltd. 1,102,950 common shares As of May 21, 2020, the aggregate market value of our outstanding common shares held by non-affiliates was approximately $5.05 million, based on 8,015,084 outsta]
CYD [CHINA YUCHAI INTERNATIONAL] 6-K: (Original Filing)
[China Yuchai International Announces Unaudited First Quarter 2020 Financial Results SINGAPORE, Singapore, May 26, 2020 China Yuchai International Limited (NYSE: CYD) on- off-road Financial Highlights for the First Quarter of 2020 Revenue decreased by 18.1% to RMB 3.4 billion (US$ 481.2 million) co]
TOUR [Tuniu] 20-F:
[] [Description of rights of each class of securities Class A Ordinary Shares Type and Class of Securities (Item 9.A.5 of Form 20-F) Each Class A ordinary share has a par value of US$0.0001 per share. The number of Class A ordinary shares that have been issued as of the last day of the financial year]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Secures $15 Million in Funding to Accelerate
[Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech C]
